Research Collaboration
Biotechnology company Compass Pathways plc (CMPS) and Greenbrook TMS Inc (GBNH) have struck a three-year research collaboration agreement to study delivery models for investigational COMP360 psilocybin treatment.
Scope of the Partnership
The collaboration aims to research and investigate models for the delivery of scalable, commercial COMP360 within healthcare systems, assuming FDA approval.
Initial Focus
The initial phase will involve research into the delivery of COMP360 at treatment centers across the U.S. catering to people suffering from treatment-resistant depression (TRD) and other mental health conditions.
Breakthrough Therapy Designation
COMP360 has been designated a “Breakthrough Therapy” by the FDA for TRD.
Future Plans
Compass has initiated a phase 3 clinical program of COMP360 in TRD with the intention to apply for FDA approval upon completion of clinical trials.
CEO Statement
“Whilst we urgently need more innovative medicines in mental health care, it is just as essential to deliver them at pace to people in greatest need,” said Compass Pathways CEO Kabir Nath.
Price Action: CMPS shares are trading lower by 5.52% at $9.08 on the last check Friday.
